Clinical Trial Update: Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

View source ↗

Summary

Clinical trial update reporting a drug use investigation for nelarabine (ARRANON G) injection 250 mg.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• ARRANON G (nelarabine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Status: COMPLETED